Medically reviewed by Susan Russell, MD Key Takeaways Squamous cell carcinoma begins in the tissues lining the air passages ...

The Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of ...

Although exposure to ultraviolet rays is a primary cause of skin cancer, factors such as your age, sex, and smoking habits also may contribute to developing this health issue.

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...

Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic ...

Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the ...

A new large-scale study has found that nicotinamide, a common vitamin B3 supplement, may significantly reduce the risk of ...

C5aR1 expression correlates with increased metastasis risk and poor survival in cSCC patients. The tumor microenvironment, especially fibroblasts, influences C5aR1 expression and cSCC progression.

Libtayo's FDA approval offers an effective adjuvant option for high-risk cutaneous squamous cell carcinoma, reducing ...

The FDA has approved cemiplimab-rwlc for adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk for ...